SMARCA5: A Potential Drug Target Or Biomarker for Various Diseases

Target Name: SMARCA5

NCBI ID: G8467

SMARCA5

SMARCA5: A Potential Drug Target Or Biomarker for Various Diseases

SMARCA5 (SMCA5_HUMAN) is a gene that has been identified as a potential drug target or biomarker for the treatment of various diseases, including cancer. The gene is located on chromosome 12 and encodes a protein known as SMARCA5, which is a key component of the nuclear envelope, which surrounds the cells and plays a crucial role in cell signaling and survival.

SMARCA5 has been shown to be involved in a variety of cellular processes, including cell signaling, cell division, and cell death. It has also been linked to the development and progression of various diseases, including cancer.

One of the most promising aspects of SMARCA5 as a drug target is its druggability. Studies have shown that SMARCA5 can be targeted with small molecules, such as inhibitors, which can inhibit its activity and lead to the collapse of the nuclear envelope and the release of nuclear contents. This could lead to the inhibition of cell signaling and the inhibition of the growth and proliferation of cancer cells.

Another promising aspect of SMARCA5 is its potential as a biomarker. The nuclear envelope is a unique structure that is present in all eukaryotic cells, and it is thought to be an attractive target for diagnostic biomarkers. Studies have shown that the expression of SMARCA5 is highly sensitive to various environmental and biological factors, such as pH, temperature, and inhibitors, which could make it an attractive target for sensitive biomarkers.

In addition to its potential as a drug target or biomarker, SMARCA5 is also of interest as a potential therapeutic target for the treatment of various diseases. The collapse of the nuclear envelope that is caused by SMARCA5's activity has been linked to the development of various diseases, including cancer. Therefore, inhibiting SMARCA5's activity could be a promising approach to the treatment of these diseases.

In conclusion, SMARCA5 is a gene that has shown promise as a potential drug target or biomarker for the treatment of various diseases. Its druggability and its potential as a therapeutic target make it an attractive candidate for further research. Further studies are needed to fully understand its potential and to develop safe and effective drugs or biomarkers for its targeting.

Protein Name: SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A, Member 5

Functions: Helicase that possesses intrinsic ATP-dependent nucleosome-remodeling activity (PubMed:12972596, PubMed:28801535). Catalytic subunit of ISWI chromatin-remodeling complexes, which form ordered nucleosome arrays on chromatin and facilitate access to DNA during DNA-templated processes such as DNA replication, transcription, and repair; this may require intact histone H4 tails (PubMed:10880450, PubMed:12434153, PubMed:28801535, PubMed:12198550, PubMed:12972596, PubMed:23911928). Within the ISWI chromatin-remodeling complexes, slides edge- and center-positioned histone octamers away from their original location on the DNA template (PubMed:28801535). Catalytic activity and histone octamer sliding propensity is regulated and determined by components of the ISWI chromatin-remodeling complexes (PubMed:28801535). The BAZ1A/ACF1-, BAZ1B/WSTF-, BAZ2A/TIP5- and BAZ2B-containing ISWI chromatin-remodeling complexes regulate the spacing of nucleosomes along the chromatin and have the ability to slide mononucleosomes to the center of a DNA template in an ATP-dependent manner (PubMed:14759371, PubMed:15543136, PubMed:28801535). The CECR2- and RSF1-containing ISWI chromatin-remodeling complexes do not have the ability to slide mononucleosomes to the center of a DNA template (PubMed:28801535). Binds to core histones together with RSF1, and is required for the assembly of regular nucleosome arrays by the RSF-5 ISWI chromatin-remodeling complex (PubMed:12972596). Involved in DNA replication and together with BAZ1A/ACF1 is required for replication of pericentric heterochromatin in S-phase (PubMed:12434153). Probably plays a role in repression of RNA polymerase I dependent transcription of the rDNA locus, through the recruitment of the SIN3/HDAC1 corepressor complex to the rDNA promoter (By similarity). Essential component of the WICH-5 ISWI chromatin-remodeling complex (also called the WICH complex), a chromatin-remodeling complex that mobilizes nucleosomes and reconfigures irregular chromatin to a regular nucleosomal array structure (PubMed:11980720, PubMed:15543136). The WICH-5 ISWI chromatin-remodeling complex regulates the transcription of various genes, has a role in RNA polymerase I transcription (By similarity). Within the B-WICH complex has a role in RNA polymerase III transcription (PubMed:16603771). Mediates the histone H2AX phosphorylation at 'Tyr-142', and is involved in the maintenance of chromatin structures during DNA replication processes (By similarity). Essential component of NoRC-5 ISWI chromatin-remodeling complex, a complex that mediates silencing of a fraction of rDNA by recruiting histone-modifying enzymes and DNA methyltransferases, leading to heterochromatin formation and transcriptional silencing (By similarity)

The "SMARCA5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SMARCA5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets